We are live on ! Find out more

846 hedge funds and large institutions have $10.4B invested in GSK in 2023 Q3 according to their latest regulatory filings, with 99 funds opening new positions, 305 increasing their positions, 268 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

226% more call options, than puts

Call options by funds: $414M | Put options by funds: $127M

43% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 69

14% more repeat investments, than reductions

Existing positions increased: 305 | Existing positions reduced: 268

9% more funds holding in top 10

Funds holding in top 10: 1112 (+1)

2% more funds holding

Funds holding: 827846 (+19)

5% more capital invested

Capital invested by funds: $9.91B → $10.4B (+$453M)

0.19% more ownership

Funds ownership: 6.79%6.98% (+0.19%)

Holders
846
Holders Change
+19
Holders Change %
+2.3%
% of All Funds
13.43%
Holding in Top 10
12
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+9.09%
% of All Funds
0.19%
New
99
Increased
305
Reduced
268
Closed
69
Calls
$414M
Puts
$127M
Net Calls
+$287M
Net Calls Change
+$213M
Name Holding Trade Value Shares
Change
Change in
Stake
RIA
301
Regal Investment Advisors
Michigan
$918K -$36.7K -1,034 -4%
Wolverine Trading
302
Wolverine Trading
Illinois
$915K +$896K +25,247 New
D.E. Shaw & Co
303
D.E. Shaw & Co
New York
$914K -$6.9M -194,461 -89%
CAM
304
Cresset Asset Management
Illinois
$912K +$13.3K +375 +2%
LCM
305
Leisure Capital Management
California
$912K +$44.8K +1,262 +5%
HKAM
306
Horizon Kinetics Asset Management
New York
$904K +$39K +1,100 +5%
NB
307
Nicolet Bankshares
Wisconsin
$903K -$348K -9,791 -28%
LI
308
Lafayette Investments
Maryland
$895K -$14.9K -420 -2%
PGFC
309
Peapack-Gladstone Financial Corp
New Jersey
$892K +$33.4K +941 +4%
RFC
310
Regions Financial Corp
Alabama
$890K +$12.5K +353 +1%
PFO
311
Pathstone Family Office
New Jersey
$887K +$588K +16,561 +211%
Lazard Asset Management
312
Lazard Asset Management
New York
$885K -$264K -7,440 -23%
KCM
313
Kanawha Capital Management
Virginia
$877K -$32.9K -928 -4%
BCAM
314
Boston Common Asset Management
Massachusetts
$876K -$201K -5,670 -19%
IMC Chicago
315
IMC Chicago
Illinois
$875K +$857K +24,139 New
ACM
316
Ativo Capital Management
Illinois
$872K -$7.17K -202 -0.8%
William Blair & Company
317
William Blair & Company
Illinois
$856K -$502K -14,130 -37%
MHC
318
Meyer Handelman Company
New York
$855K
CIA
319
Choate Investment Advisors
Massachusetts
$855K +$33.7K +949 +4%
GAA
320
Green Alpha Advisors
Colorado
$852K +$86K +2,422 +11%
JFG
321
Jefferies Financial Group
New York
$852K +$834K +23,503 New
RFM
322
Royal Fund Management
Florida
$846K +$39.2K +1,104 +5%
KeyBank National Association
323
KeyBank National Association
Ohio
$842K -$53.9K -1,518 -6%
ORC
324
O'Rourke & Company
Massachusetts
$835K -$153K -4,316 -16%
IF
325
Intrua Financial
Texas
$833K -$71.2K -2,007 -8%

GSK Hedge Fund Activity: Q3 2023 in Review

846 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2023, worth a combined $10.4B — up 4.6% from $9.91B a quarter earlier.

Buyers outnumbered sellers: 99 funds opened new GSK positions and 69 closed out — a net gain of 30 holders — while 305 added to existing stakes and 268 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $157M. The largest seller was Goldman Sachs, cutting an estimated $127M.

  • 846 institutional investors held GSK (GSK) as of Q3 2023, up from 827 in Q2 2023.
  • Funds reported $10.4B of GSK stock for Q3 2023, up 4.6% quarter-over-quarter.
  • 99 funds opened new GSK positions in Q3 2023 and 69 closed out, a net change of +30 holders.
  • The largest GSK buyer in Q3 2023 was Deutsche Bank, an estimated $157M added.
  • The largest GSK seller in Q3 2023 was Goldman Sachs, an estimated $127M sold.

Based on aggregated 13F filings for Q3 2023.